Pharmaceutical

Nxera Pharma and Antiverse to design antibodies targeting GPCRs

Nxera Pharma has entered a collaboration and licensing agreement with Antiverse to design antibodies for GPCRs.

Nov 7, 2024 - 06:00
Nxera Pharma and Antiverse to design antibodies targeting GPCRs
Nxera Pharma has entered a collaboration and licensing agreement with Antiverse to design antibodies for GPCRs.
Read the original article

Tags:

Previous Article

Trump triumphs but impact on healthcare industry remains unclear

Next Article

Ultra-processed food is causing a boom for obesity drug Ozempic

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Sen. Cassidy wants to put a stop to FDA delays in drug review process

STAT+: Sen. Cassidy wants to put a stop to FDA delays i...

Jun 8, 2023

STAT+: Judge tosses PhRMA lawsuit over Medicare power to negotiate drug prices

STAT+: Judge tosses PhRMA lawsuit over Medicare power t...

Feb 13, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

AstraZeneca completes Gracell Biotechnologies acquisiti...

Feb 24, 2024